<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397670</url>
  </required_header>
  <id_info>
    <org_study_id>CCN 003OL</org_study_id>
    <nct_id>NCT00397670</nct_id>
  </id_info>
  <brief_title>Open Label Study of the Safety and Contraceptive Efficacy of BufferGel® With Diaphragm</brief_title>
  <official_title>A Multicenter Open-Label Study of the Safety and Contraceptive Efficacy of BufferGel® Spermicide Used With Diaphragm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReProtect Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Decisions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ReProtect Inc</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the safety and contraceptive effectiveness of BufferGel
      used with a contraceptive diaphragm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date>May 2006</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contraceptive efficacy (pregnancy rate) at six months (183 days).</measure>
  </primary_outcome>
  <enrollment>200</enrollment>
  <condition>Contraception</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: BufferGel® with diaphragm</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  be healthy women, who are sexually active, at risk for pregnancy and desiring
             contraception

          -  be within the age range of 18 through 40 years inclusive

          -  be at low-risk for human immunodeficiency virus (HIV) or sexually transmitted disease
             (STD) infection, currently have (≥4 months) a single sexual partner who is also at
             low-risk for HIV or STD infection and expect to have the same partner for the duration
             of the study

          -  have a negative urine pregnancy test at the admission visit

          -  have normal cyclic menses with a usual length of 24 to 35 days over the last 2 months

          -  have a documented history of at least one spontaneous, normal menstrual cycle (two
             menses) since delivery, abortion, or after discontinuing hormonal
             contraception/hormonal therapy

          -  be willing to accept a risk of pregnancy

          -  be willing to engage in at least 4 acts of heterosexual vaginal intercourse per cycle
             for a period of approximately seven months

          -  be willing to be randomized to either study treatment as applicable

          -  be willing to be fitted with a diaphragm and use the diaphragm with test product
             during all acts of heterosexual vaginal intercourse for the duration of the study

          -  be willing to only use the test product with diaphragm as the primary method of
             contraception over the course of the study [with the exception of emergency
             contraception pills (ECPs), when indicated]

          -  be capable of using the product and diaphragm properly and agree to observe all study
             directions and requirements

        Exclusion Criteria:

          -  have a history of allergy or sensitivity to spermicides, products containing N-9,
             and/or products containing latex

          -  have a history of toxic shock syndrome

          -  have had two or more UTIs in the past year or currently have a suspected or diagnosed
             UTI or vaginitis by dipstick urinalysis or wet mount, unless treated and proof of cure
             is documented

          -  be pregnant, have a suspected pregnancy or desire to become pregnant during the course
             of the study

          -  have a history of infertility or conditions which may lead to infertility

          -  have contraindications to pregnancy (medical condition) or chronic use of class D or X
             medications

          -  have been hospitalized for pelvic inflammatory disease without a subsequent
             intrauterine pregnancy

          -  have had more than one sexual partner in the past 4 months

          -  have shared injection drug needles within the past 6 months

          -  have, or suspected to have, HIV infection

          -  have been diagnosed with genital herpes simplex virus (HSV), with the first occurrence
             (initial episode) within the 3 months prior to screening, or have clinical evidence of
             HSV on exam

          -  have been diagnosed with any other STDs (including trichomonas) in the 6 months prior
             to the screening visit

          -  be lactating or breastfeeding have had a Depo-Provera injection in the 10 months
             prior to screening

          -  have a vaginal or cervical abnormality that would interfere with the proper placement
             and retention of test product and diaphragm

        In addition, in order to be eligible to participate in the trial, potential subjects must
        state that, to her best knowledge, her sexual partner meets the following criteria:

          -  is not infertile

          -  has not been treated for Chlamydia trachomatis or N. gonorrhoeae in the past 6 months

          -  has not been previously diagnosed with, or suspected to have, HIV infection

          -  has not had more than one sexual partner in the past 4 months

          -  has not engaged in homosexual intercourse in the past 10 years

          -  has not shared injection drug needles in the past 10 years

          -  has no history of allergy or sensitivity to spermicides or products containing N-9

          -  has no history of allergy or sensitivity to products containing latex
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2006</study_first_submitted>
  <study_first_submitted_qc>November 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2006</study_first_posted>
  <last_update_submitted>November 8, 2006</last_update_submitted>
  <last_update_submitted_qc>November 8, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2006</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

